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SUMMARY Hyperhidrosis is an idiopathic condition of exaggerated 
sweat production resulting in dramatic impairments of daily activities, 
social interactions and occupational activities. The aim of the present 
study was to evaluate correlation between a subjective (Dermatology 
Life Quality Index) and an objective (Minor test) criterion and to assess 
difference in their levels over time in patients affected by axillary hy-
perhidrosis treated with botulinum toxin type A. Nineteen patients re-
ceived injections of 50 U of botulinum toxin type A per axilla. Patients 
were observed for 9 months after treatment. All patients showed 
great improvement of hyperhidrosis by Minor test and Dermatology 
Life Quality Index following treatment with botulinum toxin type A, 
with the effect persisting for 6-9 months. All patients demonstrated 
direct relationship between objective improvement documented by 
Minor test and quality of live improvement documented by Dermatol-
ogy Life Quality Index after treatment with botulinum toxin type A.
KeY WoRDS: axillary hyperhidrosis, botulinum toxin type A, Minor 
test, Dermatology Life Quality Index
INTRoDUCTIoN
Hyperhidrosis is defined as an excess of sweating 
beyond the amount needed to cool down elevated 
body temperature (1). It is a quantitative disturbance 
of sweat function, most often involving the axilla, 
sole, palm and face (2,3). It usually manifests in the 
second or third decade of life with a positive family 
history in 30%-50% of cases (4). A recent paper re-
ports the prevalence of hyperhidrosis in the United 
States to be 2.8% (7.8 million individuals), with 50.8% 
of this population (4.0 million individuals) report-
ing they have axillary hyperhidrosis (1.4% of the US 
population) (2). This condition affects both men and 
women equally (5).
It is a disabling condition in both private and profes-
sional life (6). Clothing is soiled and each day multiple 
changes are necessary. Anxiety further increases the 
production and excretion of sweat, and the problem 
is therefore self-maintained (2). This condition may be 
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idiopathic or secondary to other diseases, metabolic 
disorders, febrile illnesses, or medication use.
The pathophysiology of idiopathic focal hyperhi-
drosis remains unknown, however, a dysfunction of the 
central sympathetic nervous system is suspected (7,8). 
Treatment options for focal hyperhidrosis include topi-
cal application of aluminum chloride, administration of 
anticholinergic agents and beta-blockers, tap water ion-
tophoresis (palmar hyperhidrosis), excision and suction 
curettage of sweat glands, or transthoracic endoscopic 
sympathectomy (9-11). These therapeutic strategies 
are, however, frequently ineffective, time consuming, 
or associated with some serious side effects (12,13).
Botulinum toxin type A (BTX-A) has emerged as 
a treatment for hyperhidrosis in the past 5-6 years 
with studies showing good results (14,15). The ec-
crine sweat gland is innervated by the sympathetic 
nervous system, but its principal periglandular neu-
rotransmitter is acetylcholine. BTX-A inhibits the 
release of acetylcholine from the presynaptic mem-
brane of cholinergic neurons (16,17). BTX-A is today 
the most effective therapy for hyperhidrosis (18-20).
Numerous studies have been reported in the liter-
ature on the patient quality of life improvement (sub-
jective criterion) as evaluated with the Dermatology 
Life Quality Index (DLQI) and Minor test (objective cri-
terion) after treatment with BTX-A (21,22). The aim of 
this study was to assess (a) correlation between DLQI 
and Minor test; and (b) whether differences in their 
levels over time existed in patients with axillary hy-
perhidrosis treated with BTX-A.
PATIeNTS AND MeTHoDS
We selected 19 (7 female and 12 male) patients af-
fected by axillary primary hyperhidrosis treated with 
BTX-A and followed-up at our Department for at least 
9 months. All patients underwent physical examina-
tion with neurologic consultation, electrocardiogram 
and laboratory test (routine blood tests, urine analy-
sis, thyroid hormones, and thyroid antibodies) to ex-
clude other diseases and to classify their hyperhidro-
sis (primary or secondary, focal or generalized).
An informed consent was obtained from all pa-
tients following full written and oral explanation.
The DLQI, a valid and reliable hyperhidrosis ques-
tionnaire, was completed by patients at all scheduled 
visits (treatment, and then at 1 week, 1 month, 3-4 
months, 5 months, 6 months and 9 months). A test 
was carried out to visualize the location and involve-
ment of the hyperhidrotic area. In this test, iodine so-
lution is applied over the skin area to be tested and 
when it had dried, starch powder is applied. Sweat 
causes the mixture to turn dark brown. The identified 
hyperhidrotic area was then marked with a pen as an 
elliptical area. In order to evaluate the level of Minor 
test positivity, each axilla was subdivided into four ar-
eas (Fig. 1), which were scored 0 to 3 per area, giving 
the possible total score of 0-12 (Fig. 2) (23).
Patients were injected with a dose of 100 U BTX-
A (Botox®), 50 U per axilla. BTX-A was diluted in 5 mL 
of sterile 0.9% saline using 27 G x 1/6 0.40 x 4 mm 
needles. Each injection covered an area of about 2.25 
cm2, the volume inoculated was 0.1 mL per site cor-
responding to 2 U of BTX-A. This procedure did not 
prove painful and was well tolerated by all patients 
without local anesthesia. 
The evaluation of the results was performed by 
patient subjective reports (DLQI) and by objective 
comparison (Minor test) before treatment, and then 
at 1 week, 1 month, 3-4 months, 5 months, 6  months 
and 9 months.
Statistical Analysis
We calculated means (standard deviations) of 
quantitative variables (Minor and DLQI levels). Since 
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Figure 1. Minor test: each axilla divided into 4 areas.
Figure 2. Minor test: axillary global score 12.
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the values of Minor and DLQI were not normally dis-
tributed, differences between two periods were es-
timated by the nonparametric test for paired data 
(Wilcoxon test). Analysis of variance (ANOVA) with re-
peated measurements (F test) was used to verify dif-
ferences if Minor and DLQI levels changed over time. 
Spearman correlation coefficient (rho) was used to 
assess the correlation between Minor and DLQI levels 
at each time point. The level of significance was set at 
p<0.05. Statistical analysis was performed using SPSS, 
release 12.0 for Windows.
ReSULTS
All of the enrolled patients finished the study. The 
beginning of BTX-A action was noticed by patients 
48-72 hours after the injection. The treatment success 
was documented by DLQI and Minor test and by pre- 
and post treatment photography. All patients showed 
reduction of sweat from the first week of treatment. 
This reduction was evaluated by the objective crite-
rion. The Minor test score at the end of treatment (Mi-
nor = 7.29±2.76) was lower than the score obtained 
before therapy (Minor = 9.63±1.74) (Fig. 3). ANOVA for 
repeat measurement revealed a significant difference 
of Minor levels over time (F test = 47.007; p<0.0001). 
In this case, the observed differences over time were 
not influenced by sex (p=0.871) and age (p=0.263). 
Comparison of Minor levels before treatment and 
those recorded at each follow up period yielded a 
statistically significant difference (p from Wilcoxon 
tests <0.05). According to Minor test, anhidrosis 
lasted for 12 months in three patients, 9 months in 
eight patients, 6 months in one patient, 5 months in 
five patients, and 4 months in two patients. The me-
dian duration of treatment effect was 7 months. The 
reduction of hyperhidrotic area was associated with 
a lower quality of life impact for patients, as dem-
onstrated by DLQI scores obtained before and after 
treatment. ANOVA for repeat measurement revealed 
a significant difference in DLQI levels over time (F test 
= 12.705; p=0.001). Again, the observed differences 
over time were not influenced by sex (p=0.512) and 
age (p=0.577). More specifically, the average score at 
the end (DLQI = 9.00±4.77) of therapy was lower than 
before therapy (DLQI = 13.32±3.32) (Fig. 4). Compari-
son of DLQI levels before treatment against each fol-
low up period also yielded a statistically significant 
difference (p from Wilcoxon tests <0.001).
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Table 1. Spearman correlation coefficients between Der-
matology Life Quality Index and Minor test over time in 
patients with axillary hyperhidrosis
Time Spearman rho p
Before 0.437 0.062
7 days 0.829 <0.0001
1 month 0.708 0.001
3-4 months 0.634 0.004
5 months 0.572 0.013
6 months 0.712 0.001
9 months 0.578 0.030
Figure 3. Minor test score. Figure 4. Dermatology Life Quality Index score.
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The higher improvement evaluated by objective 
and subjective reports was achieved in one month 
after treatment and was stable until the month 6-7. 
From month 6-7, a clinically progressive relapse de-
veloped but the intensity of sweating reported by pa-
tients was lower than before treatment, although it 
would increase with time in the next months. Spear-
man correlation coefficients between DLQI and Minor 
over time are shown in Table 1. It is evident that, after 
treatment, there was always a strong correlation be-
tween these two variables, with strongest correlation 
after 7 days (p<0.0001).
DISCUSSIoN
Axillary hyperhidrosis is the most prevalent form; 
in 50% of cases, it is associated with other forms of 
localized sweating, has a familial predisposition, on-
set after puberty, and is more common in women. 
Axillary hyperhidrosis is a socially and emotionally 
disturbing condition causing wetness, staining, and 
decaying of clothes.
Botulinum toxin type A is a simple, quick and safe 
treatment for axillary hyperhidrosis, and adverse ef-
fects are rare and mild, with only one patient report-
ing mild and temporary compensatory sweating on 
his back. This treatment eliminates daily medications 
and the potential complications of medical and surgi-
cal management (24,25). The patients reported greater 
satisfaction with social life, at work, as well at leisure 
time when answering the questionnaire (DLQI) after 
7-9 months. Evaluation of the hyperhidrosis area with 
Minor test showed marked reduction of sweating until 
7-9 months. The treatment is effective and the reduc-
tion in sweat production is dramatic and lasts for at 
least 9 months, which was the duration of the study. In 
three subjects, the benefits lasted beyond 9 months.  
CoNSLUSIoN
Our results demonstrated important correlation 
between the subjective criterion (DLQI) and objective 
criterion (Minor test). In fact, comparison of the aver-
age trend for the two independent parameters, Minor 
and DLQI, suggested significant association between 
the progressive reduction of Minor related to clinical 
improvement, and reduction of DLQI values related to 
the quality of life improvement.
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